Tilray's $915M Record Revenue Fails to Spark TLRY Rally

For market participants in the cannabis sector, Tilray's headline results look strong at first glance: revenue up 11% to $915 million, adjusted EBITDA up 11% to $61.1 million, and adjusted net income nearly doubled. But the stock's failure to hold its post-earnings gains signals that investors are prioritizing per-share value and tangible U.S. exposure over top-line records. The real story for finance readers is how dilution and regulatory positioning are capping the equity story even when the income statement improves.

Tilray Brands reported fiscal 2026 results on July 28, 2026, with management touting record revenue and adjusted EBITDA. Revenue increased 11% to about $915 million, putting the company within striking distance of its $1 billion annual revenue target; adjusted EBITDA rose 11% to $61.1 million; and adjusted net income nearly doubled from $6.5 million to $12.2 million. The market initially reacted positively, producing a modest post-earnings rally. Yet by late August 2026, that rally had run its course, and Tilray shares were not participating in the renewed enthusiasm around U.S. cannabis legalization. The disconnect between record financial results and lackluster stock performance is the central puzzle for investors.

“

Revenue increased 11% to about $915 million, putting the company within striking distance of its $1 billion annual revenue target; adjusted EBITDA rose 11% to $61.1 million; and adjusted net income nearly doubled from $6.5 million to $12.2 million.

Several factors explain the hesitation. First, the headline numbers are heavily adjusted. Adjusted EBITDA and adjusted net income exclude substantial costs, and the source article notes that adjusted earnings still fell short in a key respect. For a company that has historically used share issuance to fund operations and acquisitions, dilution remains a major concern. Even as revenue climbs, per-share value may not keep pace, because the share count has grown over time. Investors in the cannabis sector have become particularly sensitive to dilution, especially after years of equity-funded losses and mergers. When management announces record top-line figures but the share price does not respond, the market is often signaling that the earnings quality or capital structure is not compelling.

Second, Tilray's exposure to the U.S. legalization catalyst is limited. The U.S. regulatory environment for cannabis appeared to be strengthening in mid-2026, but Tilray's core business is rooted in Canada and international markets. Without meaningful U.S. cultivation, distribution, or retail operations, the company may not capture the direct upside that investors are pricing into more U.S.-centric peers. The stock's inability to rally during a period of perceived regulatory tailwinds suggests that the market does not view Tilray as a primary beneficiary of potential U.S. federal reform. This is a critical limitation, because the U.S. legalization narrative has been one of the main drivers of speculative interest in cannabis stocks.

Third, the post-earnings rally was modest and short-lived. The stock initially moved higher on the guidance updates, but the bull run "ran its course" quickly, according to the analysis. This pattern often indicates that the initial buying was driven by short-covering or algorithmic reactions to a press release, rather than sustained institutional accumulation. Without a fundamental re-rating trigger, such as a major U.S. market entry, a transformative acquisition, or a return to higher-growth legacy cannabis operations, the stock is likely to remain range-bound. The article explicitly says that unless Tilray makes a big pivot back into its legacy business or another bona fide needle-moving event occurs, lackluster price action should continue.

For shareholders, the implication is that top-line growth alone is insufficient to drive equity value in this sector. The market is increasingly focused on per-share metrics, free cash flow, and tangible regulatory positioning. Tilray's adjusted EBITDA of $61.1 million is modest relative to a $915 million revenue base, implying a margin around 6.7%, and the company's net income remains small. The near doubling of adjusted net income to $12.2 million is encouraging, but it is still a thin profitability cushion for a company with significant expansion ambitions. Unless those ambitions are backed by profitable U.S. opportunities and a disciplined approach to share count, investors may continue to discount the equity.